Tenofovir alafenamide monotherapy for hepatitis B
NIHR HSRIC
Record ID 32016000364
English
Authors' objectives:
Tenofovir alafenamide is intended to be used as monotherapy for the treatment of chronic hepatitis B. Tenofovir alafenamide is a nucleotide analogue reverse transcriptase inhibitor (NtRTI) and a prodrug of tenofovir, with a potentially greater antiviral activity compared to the existing tenofovir preparation, tenofovir disoproxil fumarate. If licensed, tenofovir alafenamide monotherapy will provide an additional oral treatment option for patients with chronic hepatitis B.
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. It is the most common chronic viral infection in the world and an estimated two billion people are infected, and more than 350 million people are chronic carriers of the virus. The likelihood that infection with the virus becomes chronic depends upon the age at which a person becomes infected: 80-90% of infants infected during the first year of life and 30-50% of children infected before the age of six develop chronic infection, whilst 20-30% of adults who are chronically infected will develop cirrhosis and/or liver cancer. In the UK, approximately 78,000 people are diagnosed with chronic hepatitis B each, of whom 5% receive antiviral treatment.
Chronic hepatitis B can be treated with specific antiviral agents and these treatments can slow the progression of cirrhosis, reduce incidence of liver cancer and improve long term survival. Tenofovir is currently in two phase III trials comparing its effects on circulating hepatitis B viral DNA levels against treatment with tenofovir disoproxil fumarate. These trials are expected to complete in 2015.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/tenofovir-alafenamide-monotherapy-for-hepatitis-b/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Tenofovir
- Hepatitis B
- Antiviral Agents
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.